Futu Holdings Ltd vs Vir Biotechnology Inc. Common Stock — how do they compare? Futu Holdings Ltd trades at $107.47 (market cap $15.99B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Futu Holdings Ltd is far larger — about 8.9× Vir Biotechnology Inc. Common Stock's market cap, and Futu Holdings Ltd pays a 2.28% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| FUTU | VIR | |
|---|---|---|
Market Cap | $15.99B | $1.80B |
Volume | 931,065 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $199.04 | $11.78 |
52-Week Low | $89.76 | $5.12 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $16.33B | $1.36B |
Dividend Yield | 2.28% | — |
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $114.06, up 1.6% today, with a neutral technical signal and bullish moving averages. Revenue surged to $22.85 billion in 2025, with a net income margin of 49.62%, while valuation ratios like a P/E of 11.38 appear attractive. Recent news highlights Moomoo's expansion and a class action lawsuit deadline.
The outlook is mixed: strong fundamentals and analyst upside targets near 33% support growth, but legal risks and a recent earnings miss pose headwinds. Investors should weigh robust profitability against regulatory and competitive pressures in the financial services sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →